Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4,017 INR | +2.71% | +2.69% | +2.89% |
Apr. 26 | Weak March Quarter Earnings Weigh Down Indian Equities on Friday | MT |
Apr. 25 | Divi's Laboratories Plans Up To INR7 Billion Investment to Boost Capacity | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The opinion of analysts covering the stock has improved over the past four months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 68.95 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the past year, analysts have significantly revised downwards their profit estimates.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+2.89% | 12.52B | B | ||
+37.80% | 705B | C+ | ||
+32.82% | 583B | B | ||
-3.69% | 364B | C+ | ||
+20.18% | 332B | B- | ||
+4.90% | 291B | C+ | ||
+16.64% | 238B | B+ | ||
-4.13% | 210B | A+ | ||
+10.63% | 209B | B- | ||
+8.81% | 169B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- DIVISLAB Stock
- Ratings Divi's Laboratories Limited